JP2024517671A5 - - Google Patents

Info

Publication number
JP2024517671A5
JP2024517671A5 JP2023565204A JP2023565204A JP2024517671A5 JP 2024517671 A5 JP2024517671 A5 JP 2024517671A5 JP 2023565204 A JP2023565204 A JP 2023565204A JP 2023565204 A JP2023565204 A JP 2023565204A JP 2024517671 A5 JP2024517671 A5 JP 2024517671A5
Authority
JP
Japan
Prior art keywords
amino acid
acid residue
region
polypeptide complex
pair
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565204A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517671A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/088386 external-priority patent/WO2022223016A1/en
Publication of JP2024517671A publication Critical patent/JP2024517671A/ja
Publication of JP2024517671A5 publication Critical patent/JP2024517671A5/ja
Pending legal-status Critical Current

Links

JP2023565204A 2021-04-23 2022-04-22 ヘテロ二量体抗体およびその抗原結合断片 Pending JP2024517671A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021089400 2021-04-23
CNPCT/CN2021/089400 2021-04-23
PCT/CN2022/088386 WO2022223016A1 (en) 2021-04-23 2022-04-22 Heterodimeric antibodies and antigen-binding fragment thereof

Publications (2)

Publication Number Publication Date
JP2024517671A JP2024517671A (ja) 2024-04-23
JP2024517671A5 true JP2024517671A5 (cg-RX-API-DMAC7.html) 2025-05-01

Family

ID=83721948

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565204A Pending JP2024517671A (ja) 2021-04-23 2022-04-22 ヘテロ二量体抗体およびその抗原結合断片

Country Status (7)

Country Link
US (1) US20240182576A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326772A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024517671A (cg-RX-API-DMAC7.html)
CN (1) CN117597361A (cg-RX-API-DMAC7.html)
AU (1) AU2022261269A1 (cg-RX-API-DMAC7.html)
CA (1) CA3217487A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022223016A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202506741A (zh) * 2023-04-06 2025-02-16 美商麥迪紐有限責任公司 工程化抗體
AU2024381273A1 (en) * 2023-11-14 2026-06-04 Fortvita Biologics Inc. Anti-egfr and -her3 bispecific antibody-drug conjugate and use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341235C (en) * 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
US9527927B2 (en) * 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
KR101813708B1 (ko) * 2013-03-13 2017-12-29 (주) 아이벤트러스 소수성 상호작용 부위내에 전기적 상호작용이 도입된 단백질 및 이의 제조방법
WO2015173756A2 (en) * 2014-05-16 2015-11-19 Pfizer Inc. Bispecific antibodies
CA2980189A1 (en) * 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
KR102669686B1 (ko) * 2015-04-28 2024-05-29 자임워크스 비씨 인코포레이티드 변형된 항원 결합 폴리펩티드 작제물 및 이의 용도
JP6932700B2 (ja) * 2015-09-15 2021-09-08 アムジエン・インコーポレーテツド 4価の二重特異性抗原結合タンパク質及び4価の四重特異性抗原結合タンパク質、ならびにそれらの使用
CR20180365A (es) * 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
CA3025162A1 (en) * 2016-05-26 2017-11-30 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
AU2017356317A1 (en) * 2016-11-14 2019-05-30 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
CN110357960A (zh) * 2018-04-10 2019-10-22 广州爱思迈生物医药科技有限公司 抗体及抗体改造方法
EP3830129A4 (en) * 2018-07-30 2022-05-04 Invenra, Inc. MULTISPECIFIC TREG BINDING MOLECULES
WO2020136566A1 (en) * 2018-12-24 2020-07-02 Sanofi Multispecific binding proteins with mutant fab domains
CN115093481A (zh) * 2019-01-28 2022-09-23 正大天晴药业集团股份有限公司 新型双特异性cd3/cd20多肽复合物
AU2020283890A1 (en) * 2019-05-30 2021-12-16 Amgen Inc. Engineering the hinge region to drive antibody dimerization

Similar Documents

Publication Publication Date Title
JP7457764B2 (ja) ヘテロ二量体多重特異性抗体フォーマット
TWI821474B (zh) Cd3抗體及其藥物用途
JP6023172B2 (ja) 交差結合領域の配向性を有する二重可変領域抗体様結合タンパク質
JP2021042257A5 (cg-RX-API-DMAC7.html)
JP2023509448A5 (cg-RX-API-DMAC7.html)
JP2021525546A5 (cg-RX-API-DMAC7.html)
JP2021515798A5 (cg-RX-API-DMAC7.html)
WO2022045247A1 (ja) 抗切断型変異calr-cd3二重特異性抗体及び医薬組成物
JP2023548529A5 (cg-RX-API-DMAC7.html)
JP2020515277A5 (cg-RX-API-DMAC7.html)
RU2019134462A (ru) Антитела, связывающиеся с steap-1
JP7657591B2 (ja) 二重特異性抗原結合コンストラクト
JP2023511376A5 (cg-RX-API-DMAC7.html)
JP2022513050A5 (cg-RX-API-DMAC7.html)
JP2022500455A5 (cg-RX-API-DMAC7.html)
JP2020522250A (ja) 新規抗hsa抗体
KR20250051674A (ko) 다중특이적 항체의 중쇄 및 경쇄의 상동성 페어링을 촉진하는 돌연변이체
JP2025505650A5 (cg-RX-API-DMAC7.html)
JP2015526071A (ja) ヒトGnRH受容体に対するモノクローナル抗体のヒト化形態
Yu et al. Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds
JP2024520905A (ja) α-シヌクレイン病治療用抗体
JP2024502095A (ja) 二重または多重特異性抗体{Bi or Multi-Specific Antibody}
JP7641292B2 (ja) 抗cd19抗体、その使用方法及び製造方法
JP2024523034A5 (cg-RX-API-DMAC7.html)
JPWO2021162098A5 (cg-RX-API-DMAC7.html)